Read the third and final installment of our debate, which looks ahead at future research trends and the potential for personalized medicine.
Browsing: Cognitive/neurodegenerative disorders
Read the second installment of our Alzheimer’s genetics debate, with this part focusing on current research priorities, challenges and ethical concerns.
In the first installment of this debate, our experts discuss the contribution of genetics to Alzheimer’s risk, the differences between early- and late-onset disease, and how new technologies have advanced our understanding of this ever-expanding field.
Identification of loci associated with risk of Parkinson’s disease adds to understanding of genetic factors contributing to development of the disease
Novel research has suggested the gut microbiome is involved in multiple sclerosis and could be a treatment target.
Rachelle Doody, Global Head of Neurodegeneration at Roche, discusses her personal interest in Alzheimer’s and Roche’s current research pipeline.
This article examines physicochemical and cell-based assays and in vitro studies that have assessed the antioxidant properties of multitarget compounds.
Using FTIR spectroscopy and chemometirc techniques, researchers were able to successfully diagnose and differentiate between various neurodegenerative diseases including Alzheimer’s disease.
Ram tells Lauren Pulling about his research into the relationship between Alzheimer’s pathology and sleep spindles, shared recently at AAIC.
In a new biomarker study, RNA transcripts have shown potential as diagnostic markers of Alzheimer’s disease.